Close Menu

Precision Oncology Resources: Webinars

Thu
Mar
11
1:00 pm2021
Sponsored by
Foundation Medicine

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Genome Webinar

Medical Director, Precision Medicine
Geriatric Oncology Consortium

Chief, Precision Health and Genomics
Intermountain Healthcare

Research Scientist, Personalized Medicine Specialist,
DeBartolo Family Personalized Medicine Institute, H. Lee Moffitt Cancer Center

Co-Director, Oncology Precision Medicine Program,
Aurora Health Care

Lead Variant Scientist,
Intermountain Healthcare

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Precision medicine has been focused on the presence of activating mutations or gene amplifications. However, recent data has shown that the presence of gene fusions also offer a unique treatment opportunity, with the potential for durable clinical responses.

Our panel will discuss several such clinical cases in detail and recommend a course of treatment based on the genomic profiles of the patients.

The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

About The Series

The Virtual Molecular Tumor Board Series is an interactive and educational online program intended to highlight the key role that molecular tumor boards play in implementing precision oncology.

The series will underscore the collaborative nature of genomic medicine by assembling a multidisciplinary panel of experts who will meet virtually for four one-hour sessions. In each session, the panel will review the genomic and clinical evidence for anonymized patients who have had their tumors sequenced as part of clinical management. The panel will discuss each case and recommend a course of treatment.

Precision Oncology News would like to thank Clariifi for assistance in planning and executing this educational webinar series.

Sponsored by

Assistant Professor of Radiation Oncology,
Washington University

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Dr. Aadel Chaudhuri of Washington University will share details of the study, which applied Avenio targeted next-generation sequencing (NGS) *to plasma, tumor and urine samples acquired on the day of curative-intent surgery from prospectively enrolled oligometastatic CRC patients.

The study demonstrated that tumor-naïve plasma ctDNA analysis can sensitively and specifically detect MRD in patients with oligometastatic CRC after neoadjuvant chemotherapy, while urine-based ctDNA MRD detection is less sensitive than plasma. Dr. Chaudhuri will discuss these findings in detail.

* For Research Use Only.  Not for use in diagnostic procedures.

Sponsored by
Thu
Mar
25
1:00 pm2021
Sponsored by
Foundation Medicine

Virtual Molecular Tumor Board Series: What to Do with a ‘Negative’ Molecular Panel Case

Genome Webinar

Medical Director, Precision Medicine;
Geriatric Oncology Consortium

Chief, Precision Health and Genomics,
Intermountain Healthcare

Research Scientist, Personalized Medicine Specialist,
DeBartolo Family Personalized Medicine Institute, H. Lee Moffitt Cancer Center

Co-Director, Oncology Precision Medicine Program,
Aurora Health Care

Lead Variant Scientist,
Intermountain Healthcare

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.

The application of comprehensive genomic profiling (CGP) in patients with metastatic solid tumors aims to identify therapeutic options that were not otherwise evident with standard workup. However, CGP -- even when it analyzes patient samples against 500+ potential mutations — does not always identify an actionable target.  In these cases, clinicians still need to develop a care plan based on best evidence and individual patient goals.

Our panel will discuss several of these cases in detail and recommend next steps.

The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

About The Series

The Virtual Molecular Tumor Board Series is an interactive and educational online program intended to highlight the key role that molecular tumor boards play in implementing precision oncology.

The series will underscore the collaborative nature of genomic medicine by assembling a multidisciplinary panel of experts who will meet virtually for four one-hour sessions. In each session, the panel will review the genomic and clinical evidence for anonymized patients who have had their tumors sequenced as part of clinical management. The panel will discuss each case and recommend a course of treatment.

Precision Oncology News would like to thank Clariifi for assistance in planning and executing this educational webinar series.


Sponsored by
Tue
Mar
30
1:00 pm2021
Sponsored by
Menarini Silicon Biosystems

Circulating Tumor Cells in Breast Cancer: Understanding a Validated Diagnostic Tool for Precision Medicine

Genome Webinar

Professor of Medicine, Associate Director of Translational Research and Precision Medicine, Director of the OncoSET Precision Medicine Program,
Robert Lurie Cancer Center, Northwestern University

This webinar will provide an overview of the current state of circulating tumor cell (CTC) enumeration for clinical use in metastatic breast cancer.

Dr. Massimo Cristofanilli, Associate Director of Translational Research and Precision Medicine at Robert Lurie Cancer Center, Northwestern University, will review the evidence, as well as clinical case studies demonstrating how CTCs can be utilized in clinical practice and clinical research studies in metastatic breast cancer. 

A prominent figure in the liquid biopsy field, Dr. Cristofanilli led a pivotal study demonstrating the prognostic value of CTC enumeration using the semiautomated CellSearch technology. CellSearch has been cleared by the US Food and Drug Administration for detecting and enumerating circulating tumor cells to help manage patients with metastatic breast, prostate, and colorectal cancers.

Dr. Cristofanilli will discuss future developments and applications of CTCs in oncology. The session will wrap up with a live Q&A with Dr. Cristofanilli.

Sponsored by

Senior Scientist
Medical University of Graz

Genomics is central to the precision oncology cascade. After tissue or blood is subjected to next-generation sequencing (NGS) and bioinformatics analysis, the alterations detected must be annotated and interpreted within the context of the individual patient.

This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.

Samantha Hasenleithner of the Medical University of Graz will discuss the approach, which reflects a true clinical scenario in which both plasma and tissue analytes help inform treatment decisions. Nevertheless, this workflow poses challenges for clinicians in selecting the appropriate treatment.

Clinical decision support may help streamline these variant interpretation and treatment matching workflows, and Dr. Hasenleithner will discuss an evaluation of three such tools and her team’s experience with the Navify Mutation Profiler*.

*For Research Use Only.  Not for use in diagnostic procedures in the US.

Sponsored by